Etodolac/cyclodextrin formulations: physicochemical characterization and in vivo pharmacological studies

Abstract

The formulation of ET with CDs demonstrates relevant pharmaceutical potential in view of decreasing dose and side effects of ET. For industrial applications, HP-beta-CD appears to be the best partner for ET, as it is less expensive than gamma-CD and gives rise to higher drug solubilization than beta-CD.

Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies

“…However, the use of ETD is restricted due to its low solubility, high dose, twice a day administration, and GI side effects. Various research investigations from the literature focusing on solubility enhancement of ETD include complexation of ETD with CD, HP-β-CD, 9 solid dispersions, 10 and self-emulsifying systems. 11 In the present study, an attempt was made to investigate the effect of L-Arg, an auxiliary agent, on the solubilizing and complexation abilities of HP-β-CD with ETD through the ternary complexation technique.…”

“…However, the use of ETD is restricted due to its low solubility, high dose, twice a day administration, and GI side effects. Various research investigations from the literature focusing on solubility enhancement of ETD include complexation of ETD with CD, HP-β-CD, solid dispersions, and self-emulsifying systems …”

Desenvolvimento, caracterização e avaliação da formação de complexos de inclusão de rutina, avobenzona e ρ-metoxicinamato de octila na presença de ciclodextrinas

“…Os valores de coeficiente angular obtidos à partir da regressão linear dos diagramas de solubilidade de fases para os sistemas binários apresentaram valores inferiores a 1, assumindo estequiometria 1:1. A proporção estequiométrica 1:1 ocorre pela associação de uma única molécula hóspede na cavidade de uma molécula de CD, sendo este tipo de complexação mais relatada na literatura (CAPELLO et al, 2007;CAPELLO et al, 2009;SATHIGARI et al, 2009;CIRRI et al, 2009;BRUN et al, 2006;DOIPHONE et al, 2008).…”